Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Results of personalized biological therapy in patients with chronic rhinosinusitis with nasal polyps and severe uncontrolled bronchial asthma - real-life study. | Otolaryngol Pol | 2025 | 40008473 | PubTator, text mining | PubMed |
| Identification of blood plasma protein ratios for distinguishing Alzheimer's disease from healthy controls using machine learning. | Heliyon | 2025 | 39981365 | PubTator, text mining | PubMed |
| Effects of biologic therapy on novel indices of lung inhomogeneity in patients with severe type-2 high asthma. | BMJ Open Respir Res | 2025 | 39922604 | PubTator, text mining | PubMed |
| Personalized Medicine in Chronic Rhinosinusitis: Treatable Traits Using Biologics for Unmet Needs. | Allergy Asthma Immunol Res | 2025 | 39895599 | PubTator, text mining | PubMed |
| Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps. | Respir Med | 2025 | 39894084 | PubTator, text mining | PubMed |
| Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies. | Discov Oncol | 2025 | 39864030 | PubTator, text mining | PubMed |
| Targeting alarmins in asthma: From bench to clinic. | J Allergy Clin Immunol | 2025 | 39855362 | PubTator, text mining | PubMed |
| Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti-IL-5R Therapy and Requiring Class Switching to Anti-IL-4/13. | Int Forum Allergy Rhinol | 2025 | 39828890 | PubTator, text mining | PubMed |
| Mucus Plug Score Predicts Clinical and Pulmonary Function Response to Biologic Therapy in Patients With Severe Asthma. | J Allergy Clin Immunol Pract | 2025 | 39826645 | PubTator, text mining | PubMed |
| Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics. | J Asthma | 2025 | 39783623 | PubTator, text mining | PubMed |
| Biologics in severe asthma: a state-of-the-art review. | Eur Respir Rev | 2025 | 39778920 | PubTator, text mining | PubMed |
| Anti-IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis. | J Allergy Clin Immunol Glob | 2025 | 39736892 | PubTator, text mining | PubMed |
| Exogenous binding immunoglobulin protein (BiP) enhance immune regulatory phenotype in ex-vivo Mtb infected PBMCs stratified based on QuantiFERON response. | Cytokine | 2025 | 39671882 | PubTator, text mining | PubMed |
| Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. | Lancet Respir Med | 2025 | 39615502 | PubTator, text mining | PubMed |
| Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2025 | 39536291 | PubTator, text mining | PubMed |
| Targeting of the IL-5 pathway in severe asthma reduces mast cell progenitors. | J Allergy Clin Immunol | 2025 | 39521285 | PubTator, text mining | PubMed |
| Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies. | Eur J Clin Invest | 2025 | 39387173 | PubTator, text mining | PubMed |
| A comparison of the impact of anti-IL5/5r therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting. | J Asthma | 2025 | 39235972 | PubTator, text mining | PubMed |
| Effect of benralizumab on histopathology and inflammatory signatures in a clinical cohort of eosinophilic esophagitis. | Dis Esophagus | 2025 | 38986036 | PubTator, text mining | PubMed |
| Gαi1/3 signaling mediates IL-5-induced eosinophil activation and type 2 inflammation in eosinophilic chronic rhinosinusitis. | Front Immunol | 2024 | 39840047 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=9